semaglutide shortage update fda status january 2025 declares end to Wegovy and Ozempic GLP-1 No Longer on FDA's – The Wegovy Shortage Continues, Leaving

Your provider determines your exact dosing plan, and compounded protocols can differ slightly from brand-name labeling always follow the instructions on your prescription

The FDA issued a formal proposal on April 30, 2026 that, if finalized, would further restrict outsourcing-facility compounding of semaglutide, tirzepatide, and liraglutide from bulk substances under section 503B

These trials are mostly based on composite reductions in MACEs (similar to the original ELIXA trial endpoint)

Reside in Louisiana or outside the U.S.: The service is not currently available in Louisiana or internationally

Tirzepatide targets GIP and GLP-1 receptors and has approved uses in some jurisdictions

Contact: [email protected] Our Mission CASPR is a new non-profit research and policy organization focused on opportunities for breakthrough progress towards reducing addiction